Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Investors Should Avoid Robinhood Stock At All Costs

By Chris Lau, InvestorPlace Contributor

Robinhood’s stock-based compensation is too high and its crypto plans may prove a distraction, prompting a further decline in HOOD stock.

Buy Microsoft Stock as Growth Drivers Accelerate

By Chris Lau, InvestorPlace Contributor

After it posted strong results, Microsoft stock is proving it is a good deal for investors seeking a balance of growth and value.

Why AT&T Is a Best-of-Both-Worlds Investment

By Chris Lau, InvestorPlace Contributor

When it comes to T stock, investors get a steady dividend as mobility subscriptions grow as well as an entertainment spinoff this year.

Take a Leap Into Novavax Stock After Vaccine Sales Start

By Chris Lau, InvestorPlace Contributor

Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.

Why Hyper-Growth in AI Will Lift Upstart

By Chris Lau, InvestorPlace Contributor

Upstart has a unique algorithm powered by machine learning and artificial intelligence to handle credit approvals that will boost UPST stock.

Load More